SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation
Wenjing Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianwei Wang(Zhejiang Cancer Hospital), Xia Xiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Conghui Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhongqin Tian(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaobo Lei(University of Louisiana at Lafayette), Li Li(Henan University of Science and Technology), Zichun Xiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lili Ren(Huaibei Normal University), Xiaojing Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhuo Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 146
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
|Chinese Medical Journal|2020|1.4k
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study
|The Lancet|2021|1.1k